

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W WX0000003826 F 12/05/1988 34 Y

NRAS Mutation Analysis Iver QCR Specimen Source Liver QCR Paraffin Block Number: AAS123-45678 QCR							
Test NameResultFlagRef-RangesUnitsSiteNRAS Mutation AnalysisSpecimen SourceLiverOCRParaffin Block Number:AAS123-45678OCRNRAS Mutation AnalysisDETECTEDABNRAS Mutation AnalysisDETECTEDABNRAS mutation, (c.35G>T (Gly12Val), 26.5%), was detected. Please see below for additional details.NRAS mutation, (c.35G>T (Gly12Val), 26.5%), was detected. Please see below for additional details.Activating NRAS oncogenic mutations are detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias.In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay.This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has		Referral Testi	ng				
NRAS Mutation Analysis Liver OCR: Specimen Source Liver OCR: Paraffin Block Number: AAS123-45678 OCR: NRAS Mutation Analysis DETECTED AB OCR: NRAS Mutation (c.35G>T (Gly12Val), 26.5%), was detected. Please see DETECTED DETECTED NRAS mutation, (c.35G>T (Gly12Val), 26.5%), was detected. Please see Detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias. In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has		Collected: 09	/12/2023	10:43	Received:	09/12/2023	10:43
Specimen Source Liver QCR Paraffin Block Number: AAS123-45678 QCR NRAS Mutation Analysis DETECTED AB Reference Range: NOT DETECTED AB NRAS mutation, (c.35G>T (Gly12Val), 26.5%), was detected. Please see below for additional details. Activating NRAS oncogenic mutations are detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias. In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS group (MTM 002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has	Test Name	Result	<u>Flag</u> I	<u>Ref-Ranges</u>	<u>L</u>	<u>Jnits</u>	<u>Site</u>
NOT DETECTED NRAS mutation, (c.35G>T (Gly12Val), 26.5%), was detected. Please see below for additional details. Activating NRAS oncogenic mutations are detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias. In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has	Specimen Source Paraffin Block Number:	AAS123-45678	AB				QCRL QCRL QCRL
<pre>below for additional details. Activating NRAS oncogenic mutations are detected in a wide variety of cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias. In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has</pre>	5						
<pre>cancers, including colorectal carcinomas, melanomas and acute myeloid leukemias. In fixed tissue samples, the area of tumor was grossly macrodissected prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has</pre>		l2Val), 26.5%), waa	s detect	ced. Pleas	se see		
prior to DNA extraction. Nucleic acid was subjected to Next-generation sequencing of exons 2, 3 and 4 of NRAS gene (NM_002524.4). The sensitivity for mutation detection of the assay is 5% mutant allele in a background of normal alleles. Insertions up to 30bp and deletions up to 48bp have been successfully detected by this assay. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute . It has	cancers, including colorectal				-		
have been determined by Quest Diagnostics Nichols Institute . It has	prior to DNA extraction. Nucle seqeuencing of exons 2, 3 and sensitivity for mutation detec a background of normal alleles	eic acid was subject 4 of NRAS gene (NM ction of the assay s. Insertions up to	ted to N _002524. is 5% mu 30bp ar	Next-gener .4). The utant alle	ation		
pursuant to the CLIA regulations and is used for clinical purposes.	have been determined by Quest not been cleared or approved b	Diagnostics Nichols by FDA.This assay ha	s Instit as been	tute . It validated	has l		
Laboratory results and submitted clinical information reviewed by Bernard Joseph Ilagan, MD, MHA, FACMG, CGMBS. Test Performed at: Quest Diagnostics Nichols Institute	Bernard Joseph Ilagan, MD, MHA Test Performed at: Quest Diagnostics Nichols Inst	A, FACMG, CGMBS.	ation re	eviewed by	7		
33608 Ortega Highway San Juan Capistrano, CA 92675-2042 I Maramica MD, PhD, MBA		5-2042 I Maramio	ca MD, B	PhD, MBA			
Performing Site:				OTDANO 20222 -			-
QCRL: QUEST DIAGNOSTICS REFERENCE LAB CAPISTRANO 33608 Ortega Highway San Juan Capistrano CA 92675 Reported Date: 2023.09.12 10:43 NRMUA	QCF						

Reported Date: 2023.09.12 10:43 NRMUA

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

Ordered By: KAJAL SITWALA, MD, PhD WX0000000002353